Am. J. Respir. Crit. Care Med., Vol 154, No. 4, Oct 1996, 843-849.
Heterogeneity of allergic airway responses in sheep: differences in signal transduction?
T Ahmed, J D'Brot, WM Abraham, J Lucio, R Mendelssohn, MJ Robinson, S Shakir and B Sanpedro
The Division of Pulmonary Disease, University of Miami School of Medicine, Mount Sinai Medical Center, Miami Beach, Florida, USA.
In preliminary studies we have observed that inhaled heparin blocks
antigen-induced airway responses in sheep that develop only acute responses
to inhaled antigen (acute responders), but not in sheep that develop both
acute and later responses (dual responders). Because heparin is an
antagonist of inositol triphosphate (IP3) (one of the pathways involved in
stimulus-secretion-coupling in mast cells), the differential effect of
inhaled heparin in acute responders and dual responders might indicate the
involvement of different signaling pathways during IgE-mediated mast cell
reactions. Therefore, in this study we compared the effects of heparin on
antigen-induced bronchconstriction, allergic cutaneous reaction, and
histamine release into bronchoalveolar lavage fluid (BAL) in sheep that
develop only acute responses or dual responses to inhaled Ascaris suum
antigen. Specific lung resistance (SRL) was measured in 21 sheep (eight
acute responders; 13 dual responders) before and after inhalation challenge
with antigen, without and after pretreatment with inhaled heparin (1,000
units/kg). Histamine in BAL was measured by RIA before and after segmental
antigen challenge, without and after pretreatment with inhaled heparin
(eight acute responders; eight dual responders). In acute responders, mean
+/- SE SRL increased by 197 +/- 21% with antigen; this was prevented by
inhaled heparin (deltaSRL = 15 +/- 7%; p < 0.05). In dual responders,
inhaled heparin had no effect on antigen- induced early (deltaSRL = 328 +/-
51% versus 305 +/- 76%) or late (deltaSRL = 201 +/- 33% versus 163 +/- 15%)
responses. After segmental antigen challenge, BAL mean +/- SE histamine
increased from 2.09 +/- 0.8 nM to 75.4 +/- 21.1 nM in acute responders and
1.58 +/- 0.7 nM to 66.8 +/- 27.3 nM in dual responders (p < 0.01).
Inhaled heparin inhibited the increase in BAL histamine by 81% in acute
responders (p < 0.05) and by only 19% in dual responders (p = NS). As
was seen in the airways, heparin attenuated the allergic cutaneous reaction
in acute responders by 46% (p < 0.05), but it was ineffective in dual
responders. In contrast, H-7, a nonspecific protein kinase C inhibitor,
attenuated the cutaneous reaction in dual responders by 28% (p < 0.05),
but it was ineffective in acute responders. These data suggest that
heterogeneity of allergic airway response is related to difference in mast
cell signal transduction; IP3 is the predominant second messenger in acute
responders, whereas non-IP3 pathways may be involved in dual responders.
This article has been cited by other articles:

|
 |

|
 |
 
W. M. Abraham, A. Ahmed, I. Serebriakov, I. T. Lauredo, J. Bassuk, J. A. Adams, and M. A. Sackner
Whole-Body Periodic Acceleration Modifies Experimental Asthma in Sheep
Am. J. Respir. Crit. Care Med.,
October 1, 2006;
174(7):
743 - 752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ahmed, J. Ungo, M. Zhou, and C. Campo
Inhibition of allergic late airway responses by inhaled heparin-derived oligosaccharides
J Appl Physiol,
May 1, 2000;
88(5):
1721 - 1729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. AHMED, B. J. GONZALEZ, and I. DANTA
Prevention of Exercise-induced Bronchoconstriction by Inhaled Low-molecular-weight Heparin
Am. J. Respir. Crit. Care Med.,
August 1, 1999;
160(2):
576 - 581.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
C. Campo, J. F. Molinari, J. Ungo, and T. Ahmed
Molecular-weight-dependent effects of nonanticoagulant heparins on allergic airway responses
J Appl Physiol,
February 1, 1999;
86(2):
549 - 557.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. MOLINARI, C. CAMPO, S. SHAKIR, and T. AHMED
Inhibition of Antigen-induced Airway Hyperresponsiveness by Ultralow Molecular-weight Heparin
Am. J. Respir. Crit. Care Med.,
March 1, 1998;
157(3):
887 - 893.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Martinez-Salas, R. Mendelssohn, W. M. Abraham, B. Hsiao, and T. Ahmed
Inhibition of allergic airway responses by inhaled low-molecular-weight heparins: molecular-weight dependence
J Appl Physiol,
January 1, 1998;
84(1):
222 - 228.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1996 American Thoracic Society
|
|
|